Incyte Corporation
FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS

Abstract:

This application relates to compounds of Formula (I): ##STR00001## or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.